Medicinal Chemistry Research

, Volume 23, Issue 11, pp 4915–4925 | Cite as

Substituted phenyl containing 1,3,4-oxadiazole-2-yl-but-2-enamides: synthesis and preliminary evaluation as promising anticonvulsants

  • Nadeem Siddiqui
  • Md. Jawaid AkhtarEmail author
  • M. Shahar Yar
  • Priya Ahuja
  • Waquar Ahsan
  • Sharique Ahmed
Original Research


A series of 3-(4-substitutedphenyl)-N-(5-(4-substitutedphenyl-1,3,4-oxadiazol-2-yl)but-2-enamide were synthesized using pharmacophoric elements for in vivo anticonvulsant activity yielding two potent candidates (4d and 4j) in the Phase I and Phase II screening employing maximal electroshock seizure and subcutaneous pentylenetetrazole test having minimal neurotoxicity. Their Phase II screen depicted an increment of nearly 2–10 times for MES and 7–67 folds for scPTZ in the therapeutic index and protective index—the two mainstays in the drug discovery.


Epilepsy Neurotoxicity Pharmacophore Liver enzyme estimation 



The authors are thankful to Jamia Hamdard New Delhi, India, for providing facility for research work. One of the authors (M. Jawaid Akhtar) expresses thanks to University Grant Commission (UGC) New Delhi, India, for the financial assistance.


  1. Alamsirad A, Tabatabai SA, Faizi M, Kebriaeezadeh A, Mehrabi N, Dalvandi A, Shafiee A (2004) Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2-flurophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles. Bioorg Med Chem Lett 14:6057–6059CrossRefGoogle Scholar
  2. Anticonvulsant Screening Project, Anti-epileptic Drug Development Program, National Institute of Health, DHEW Pub (NIH), (US) (1978) p 78–1093Google Scholar
  3. Azam F, Madi AM, Ali HI (2012) Molecular docking and prediction of pharmacokinetic properties of dual mechanism drugs that block MAO-B and adenosine A2A receptors for the treatment of parkinson’s disease. J Young Pharm 4(3):184–192PubMedCentralCrossRefPubMedGoogle Scholar
  4. Dimmock JR, Pandeya SN, Quail JW, Pugazhenthi U, Allen TM, Kao GY, Balzarini JD, De Clercq E (1995) Evaluation of the semicarbazones, thio semicarbazones and biscarbhydrazones of some aryl alicylic ketones for anticonvulsant and other biological properties. Eur J Med Chem 39:303–314CrossRefGoogle Scholar
  5. Dimmock JR, Puthucode RN, Smith JM, Hetheriengton M (1996) (Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. J Med Chem 39:3984–3997CrossRefPubMedGoogle Scholar
  6. Ertl P, Rohde B, Selzer PJ (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. Med Chem 43:3714–3717CrossRefGoogle Scholar
  7. Farrar VA, Ciechanowicz-Rutkowska M, Grochowski J, Serda P, Pilati T, Filippini G, Hinko CN, El-Assadi A, Moore JA, Edafiogho IO, Andrews CW, Cory M, Nicholson JM, Scott KR (1993) Synthesis and calculated log P correlation of imidooxy anticonvulsants. J Med Chem 36:3517–3525CrossRefPubMedGoogle Scholar
  8. Kashaw SK, Gupta V, Kashaw V, Mishra P, Stables JP, Jain NK (2010) 3-[5-(4-Substituted)phenyl-1,3,4-oxadiazole-2yl]-2-styrylquinazoline-4(3H)-ones. Med Chem Res 19:250–261CrossRefGoogle Scholar
  9. Kaushik D, Khan SA, Chawla G, Kumar S (2010) N’-[(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity. Eur J Med Chem 45:3943–3949CrossRefPubMedGoogle Scholar
  10. King EJ, Armstrong AR (1934) A convenient method for determining serum and bile phosphatase activity. Can Med Assoc J 31:376–381PubMedCentralPubMedGoogle Scholar
  11. Krall AC, Penny JK, While BG, Kupferberg HG, Swinyard EA (1978) Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 19:409–428CrossRefPubMedGoogle Scholar
  12. Lankau H, Unverferth K, Grunwald C, Hartenhauer H, Heinecke K, Bernoster K, Dost R, Egerland U, Rundfeldt C (2007) New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity. Eur J Med Chem 42:873–879CrossRefPubMedGoogle Scholar
  13. Litchfield JT, Wilcoxon FA (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113PubMedGoogle Scholar
  14. Malawska B (2005) Current topics. Med Chem 5:69–85Google Scholar
  15. Nanavati SM, Silverman RB (1989) Design of potential anticonvulsant agents: mechanistic classification of GABA aminotransferase inactivators. J Med Chem 32:2413–2421CrossRefPubMedGoogle Scholar
  16. Reinhold JG (1953) Standard methods in clinical chemistry. In: Reiner M (ed). Academic Press, New York, p 88–90Google Scholar
  17. Reitman S, Frankel S (1957) A colorimetric method for the determination of glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28:56–58PubMedGoogle Scholar
  18. Shingalapur RV, Hosamani KM, Keri RS, Hugar MH (2010) Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. Eur J Med Chem 45:1753–1759CrossRefPubMedGoogle Scholar
  19. Storici P, Capitani P, De Biase D, Moser M, John RA, Jansonius JN, Schirmer T (1999) Design of a conformationally restricted analogue of the antiepilepsy drug Vigabatrin that directs its mechanism of inactivation of gamma-aminobutyric acid aminotransferase. Biochem 38:8628–8634CrossRefGoogle Scholar
  20. Wong MG, Dejina JA, Andrews PR (1986) Conformational analysis of clinically active anticonvulsant drugs. J Med Chem 29:562–571CrossRefPubMedGoogle Scholar
  21. Yogeeswari P, Sriram D, Saraswat V, Vaigunda RJ, Mohan KM, Murugesan S, Thirumurugan R (2003) Synthesis and anticonvulsant and neurotoxicity evaluation of N4-phthalimido phenyl (thio) semicarbazides. Eur J Pharm Sci 20:341–346CrossRefPubMedGoogle Scholar
  22. Zarghi A, Faizi M, Shafaghi B, Ahadian A, Khojastehpoor HR, Zanganch V, Tabatabai SA, Shafiee A (2009) Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazole as benzodiazepine receptor agonists. Bioorg Med Chem Lett 15:3126–3129CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Nadeem Siddiqui
    • 1
  • Md. Jawaid Akhtar
    • 1
    Email author
  • M. Shahar Yar
    • 1
  • Priya Ahuja
    • 1
  • Waquar Ahsan
    • 2
  • Sharique Ahmed
    • 3
  1. 1.Department of Pharmaceutical Chemistry, Faculty of PharmacyHamdard UniversityNew DelhiIndia
  2. 2.Department of Pharmaceutical Chemistry, College of PharmacyJazan UniversityJazanKingdom of Saudi Arabia
  3. 3.Allied Health Division, College of Health SciencesMinistry of HealthManamaBahrain

Personalised recommendations